2023
Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study
Webster J, Luskin M, Rimando J, Blackford A, Zeidan A, Sharon E, Streicher H, DeAngelo D, Luznik L, Gojo I. Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study. Blood 2023, 142: 966. DOI: 10.1182/blood-2023-191109.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsMixed phenotype acute leukemiaRelapse-free survivalOverall survivalAcute lymphoblastic leukemiaComplete remissionPD-1Checkpoint inhibitorsExtramedullary diseaseAdverse eventsBM blastsGrade 3Positive B-cell acute lymphoblastic leukemiaResponse rateImmune-related adverse eventsB-cell acute lymphoblastic leukemiaMulti-center phase IPhase IDose-escalation schemaNon-hematologic toxicitiesMedian overall survivalDose-escalation studyPD-L1 expressionDuration of responseT cell subpopulations
2018
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
Uy N, Nadeau M, Stahl M, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. Journal Of Blood Medicine 2018, 9: 67-74. PMID: 29713210, PMCID: PMC5908210, DOI: 10.2147/jbm.s136575.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChemotherapy-based approachesInotuzumab ozogamicinAcute lymphoblastic leukemiaB-ALLLymphoblastic leukemiaChimeric antigen receptor (CAR) T-cell productBispecific T-cell engager blinatumomabAcute B-cell lymphoblastic leukemiaPhiladelphia chromosome-positive diseaseSecond-line salvage therapyB-cell lymphoblastic leukemiaExcellent clinical activityT-cell productsRelapsed B-ALLCD22 monoclonal antibodySalvage therapyAdult patientsSupportive careCell transplantationLeukemic blastsSuperior survivalClinical trialsClinical activityOzogamicinClinical data